- Advertisement -
- Advertisement -

Coeli Enjoys Atai Success

- Advertisement -

Stockholm (HedgeNordic) – Germany-based biotech Atai Life Sciences, backed by billionaire investor Peter Thiel, Mike Novogratz, Atai founder Christian Angermayer’s own family office and smaller investors such as Malmö-based money manager Mikael Petersson, went public last week on the NASDAQ. The psychedelics biotech start-up’s shares currently trade above $18 apiece, translating into a market capitalization of about $2.8 billion.

Mikael Petersson, Portfolio Manager of Coeli Absolute European Equity

In September 2018, the biotech start-up completed a Series A financing round of $24.4 million to make psychedelic drugs to treat mental health disorders. Long/short equity fund Coeli Absolute European Equity, founded and managed by Mikael Petersson out of Malmö, invested close to $1 million in the Series A round alongside a select group of investors that also featured well-known entrepreneur and venture capitalist Peter Thiel. After a Series B financing round of $43 million in March of last year, a $125 million Series C financing at the end of 2020 and a Series D fundraising of $157 million earlier this year, ATAI Life Sciences raised an additional $225 million through its initial public offering last week at the IPO price of $15.

“Committed to our public mission, now more than ever. atai Life Sciences is now a public company, listed on Nasdaq — a huge step for us, but we have so much work to do.”

“Committed to our public mission, now more than ever. atai Life Sciences is now a public company, listed on Nasdaq — a huge step for us, but we have so much work to do,” Atai Life Sciences writes on LinkedIn post. “Becoming a public company will help atai access the resources necessary to deliver on our goals, to deliver positive impact and improved treatment options for mental health disorders.”

“Becoming a public company will help atai access the resources necessary to deliver on our goals, to deliver positive impact and improved treatment options for mental health disorders.”

“The world we’re building is a bad place for our brain, so mental health issues will go up. But I do think we have some real shots in our portfolio to end the mental health crisis,” Atai’s founder and Chairman, Christian Angermayer, said on CNBC’s “Squawk Box” on Friday last week. Atai Life Sciences is the brainchild of Angermayer, who was joined by co-founder and current CEO Florian Brand to “enable people to live healthier and happier lives” by “bringing back formerly vilified drugs like psychedelics into the legal realm.”

“We are very proud and grateful of being an early investor in Atai Life Sciences AG. A company with the very important mission to end the mental health crisis in the world.”

“We are very proud and grateful of being an early investor in Atai Life Sciences AG. A company with the very important mission to end the mental health crisis in the world,” says Petersson, the founder and portfolio manager of Coeli Absolute European Equity. “From a dinner in Copenhagen to today’s form and shape in less than three years. Incredible!” he continues. “Big congratulations to Christian Angermayer and Florian Brand and the whole team for the success and we look forward to the coming years.”

Image courtesy of Nasdaq

close

Subscribe to HedgeBrev, HedgeNordic’s weekly newsletter, and never miss the latest news!

Our newsletter is sent once a week, every Friday.

Eugeniu Guzun
Eugeniu Guzun
Eugeniu Guzun serves as a data analyst responsible for maintaining and gatekeeping the Nordic Hedge Index, and as a journalist covering the Nordic hedge fund industry for HedgeNordic. Eugeniu completed his Master’s degree at the Stockholm School of Economics in 2018. Write to Eugeniu Guzun at eugene@hedgenordic.com

Latest

Most Popular This Week

Voices

Request for Proposal

- Advertisement -

Latest Articles

Alcur’s Third Win in a Row

Stockholm (HedgeNordic) – Alcur Fonder’s first hedge fund, Alcur, has been named “Hedge Fund of the Year” by Swedish business magazine Privata Affärer for...

Lynx is Fund Company of the Year, Says Privata Affärer

Stockholm (HedgeNordic) – Lynx Asset Management has been named “Fund Company of the Year” by Swedish business magazine Privata Affärer. The distinction comes after...

RFP: Absolute Return Multi-Strategy/Fund of Funds

(Global Fund Search) - A Danish Institutional Investor is searching for an absolute return strategy for an allocation of EUR 40 million. The mandate...

Brummer Multi-Strategy Navigates 2022’s “Perfect” Storm

Stockholm (HedgeNordic) – 2022 experienced a “perfect” inflation storm due to an unprecedented amount of monetary and fiscal policy stimulus during the pandemic, war,...

Dream Comes True for Grönblom

Stockholm (HedgeNordic) – Ernst Grönblom had been running his high-conviction strategy of cherry-picking the stock market’s undervalued future winners under the umbrella of United...

Boarding the Broader Alternatives Ship

Stockholm (HedgeNordic) – Tore Davidsen, portfolio manager of SEB Eureka Fixed Income Relative Value since its launch in 2018, will join BankInvest as Senior...